PortfoliosLab logoPortfoliosLab logo
PSIL vs. IDNA
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

PSIL vs. IDNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in AdvisorShares Psychedelics ETF (PSIL) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, PSIL achieves a 20.15% return, which is significantly higher than IDNA's 10.31% return.


PSIL

1D
-2.57%
1M
1.88%
YTD
20.15%
6M
23.74%
1Y
65.52%
3Y*
9.55%
5Y*
10Y*

IDNA

1D
0.73%
1M
-2.56%
YTD
10.31%
6M
8.52%
1Y
40.87%
3Y*
6.74%
5Y*
-8.42%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

PSIL vs. IDNA - Yearly Performance Comparison


2026 (YTD)20252024202320222021
PSIL
AdvisorShares Psychedelics ETF
20.15%74.55%-19.50%-25.12%-67.24%-41.98%
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
10.31%17.26%-0.72%-7.63%-42.28%-18.92%

Correlation

The correlation between PSIL and IDNA is 0.51, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.51

Correlation (3Y)
Calculated over the trailing 3-year period

0.48

Correlation (All Time)
Calculated using the full available price history since Sep 17, 2021

0.49

The correlation between PSIL and IDNA has been stable across timeframes, ranging from 0.48 to 0.51 - a consistent structural relationship.

PSIL vs. IDNA - Sectors Allocation Comparison


Sectors
PSIL
IDNA

Healthcare

100.0%
97.8%

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Financial Services

-

-

Industrials

-

0.4%

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

PSIL
100.0%
IDNA
97.8%

Basic Materials

PSIL

-

IDNA

-

Communication Services

PSIL

-

IDNA

-

Consumer Cyclical

PSIL

-

IDNA

-

Consumer Defensive

PSIL

-

IDNA

-

Energy

PSIL

-

IDNA

-

Financial Services

PSIL

-

IDNA

-

Industrials

PSIL

-

IDNA
0.4%

Real Estate

PSIL

-

IDNA

-

Technology

PSIL

-

IDNA

-

Utilities

PSIL

-

IDNA

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

PSIL vs. IDNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PSIL
PSIL Risk / Return Rank: 4848
Overall Rank
PSIL Sharpe Ratio Rank: 4646
Sharpe Ratio Rank
PSIL Sortino Ratio Rank: 4343
Sortino Ratio Rank
PSIL Omega Ratio Rank: 4343
Omega Ratio Rank
PSIL Calmar Ratio Rank: 6666
Calmar Ratio Rank
PSIL Martin Ratio Rank: 4343
Martin Ratio Rank

IDNA
IDNA Risk / Return Rank: 5555
Overall Rank
IDNA Sharpe Ratio Rank: 4848
Sharpe Ratio Rank
IDNA Sortino Ratio Rank: 4949
Sortino Ratio Rank
IDNA Omega Ratio Rank: 4242
Omega Ratio Rank
IDNA Calmar Ratio Rank: 7676
Calmar Ratio Rank
IDNA Martin Ratio Rank: 6161
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PSIL vs. IDNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for AdvisorShares Psychedelics ETF (PSIL) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


PSILIDNADifference
Sharpe ratioReturn per unit of total volatility

-0.10

Sortino ratioReturn per unit of downside risk

-0.30

Omega ratioGain probability vs. loss probability

1.27

1.27

0.00

Calmar ratioReturn relative to maximum drawdown

3.23

3.85

-0.62

Martin ratioReturn relative to average drawdown

6.82

10.98

-4.15

PSIL vs. IDNA - Sharpe Ratio Comparison

The current PSIL Sharpe Ratio is 1.58, which is comparable to the IDNA Sharpe Ratio of 1.68. The chart below compares the historical Sharpe Ratios of PSIL and IDNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


PSILIDNADifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.58

1.68

-0.10

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.30

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.42

0.10

-0.52

Drawdowns

PSIL vs. IDNA - Drawdown Comparison

The maximum PSIL drawdown since its inception was -92.72%, which is greater than IDNA's maximum drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for PSIL and IDNA.


Loading charts...

Drawdown Indicators


PSILIDNADifference

Max Drawdown

Largest peak-to-trough decline

-92.72%

-68.26%

-24.46%

Max Drawdown (1Y)

Largest decline over 1 year

-20.38%

-10.66%

-9.72%

Max Drawdown (3Y)

Largest decline over 3 years

-64.62%

-29.73%

-34.89%

Max Drawdown (5Y)

Largest decline over 5 years

-68.26%

Current Drawdown

Current decline from peak

-76.63%

-45.61%

-31.02%

Average Drawdown

Average peak-to-trough decline

-76.76%

-36.24%

-40.52%

Ulcer Index

Depth and duration of drawdowns from previous peaks

9.63%

3.73%

+5.90%

Volatility

PSIL vs. IDNA - Volatility Comparison

AdvisorShares Psychedelics ETF (PSIL) has a higher volatility of 9.76% compared to iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) at 7.18%. This indicates that PSIL's price experiences larger fluctuations and is considered to be riskier than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


PSILIDNADifference

Volatility (1M)

Calculated over the trailing 1-month period

9.76%

7.18%

+2.58%

Volatility (6M)

Calculated over the trailing 6-month period

27.89%

17.98%

+9.91%

Volatility (1Y)

Calculated over the trailing 1-year period

41.80%

24.48%

+17.32%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

63.15%

28.42%

+34.73%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

63.15%

29.53%

+33.62%

PSIL vs. IDNA - Expense Ratio Comparison

PSIL has a 1.00% expense ratio, which is higher than IDNA's 0.47% expense ratio.


Dividends

PSIL vs. IDNA - Dividend Comparison

PSIL's dividend yield for the trailing twelve months is around 8.32%, more than IDNA's 1.07% yield.


PositionTTM2025202420232022202120202019
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
1.07%1.18%0.98%1.04%0.54%0.70%0.26%0.80%
PSIL
AdvisorShares Psychedelics ETF
8.32%10.95%1.49%0.24%2.91%0.00%0.00%0.00%

Frequently Asked Questions


PSIL and IDNA have a correlation of 0.51, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

PSIL has higher volatility (9.76%) compared to IDNA (7.18%). In terms of maximum drawdown, PSIL dropped -92.72% vs IDNA's -68.26%.

On 3-year performance, PSIL leads with 9.55% vs 6.74% for IDNA. On fees, IDNA is cheaper at 0.47% per year. On volatility, IDNA has been the lower-risk option at 7.18%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 3-year period, PSIL has performed better with a 9.55% return vs 6.74%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

IDNA is cheaper with a 0.47% expense ratio, compared with 1.00% for PSIL.

PSIL has the higher dividend yield at 8.32%, compared with 1.07% for IDNA.

They also come from different issuers: AdvisorShares and iShares. Their fees differ too: 1.00% for PSIL and 0.47% for IDNA.

IDNA currently has the higher Sharpe Ratio (1.68 vs 1.58), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for PSIL and IDNA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer